Interestingly, a recent report identified disruptions in nucleotide biosynthesis as a potential cause of the selective toxicity of class I HDAC inhibition toward NRF2-dependent cancer cells (Karagiannis et al, 2024). The gene discussed is NFE2L2; the disease is cancer.